Basit öğe kaydını göster

dc.contributor.authorKöse, Duygu
dc.contributor.authorKöse, Ahmet
dc.contributor.authorHalıcı, Zekai
dc.contributor.authorGürbüz, Muhammet Ali
dc.contributor.authorMaman, Adem
dc.contributor.authorYayla, Muhammed
dc.date.accessioned2022-09-29T08:25:00Z
dc.date.available2022-09-29T08:25:00Z
dc.date.issued2021en_US
dc.identifier.urihttps://dergipark.org.tr/tr/download/article-file/1775561
dc.identifier.urihttps://hdl.handle.net/20.500.12868/1713
dc.description.abstractAim: Melatonin promoted osteoblast differentiation and causes an increase in levels of markers of bone differentiation and proliferation. Ramelteon (RAMEL) activates melatonin receptors and binds to these receptors as non-selective. In this study, we investigated the preventive effects of the melatonin agonist RAMEL on osteoporosis by radiological, histological, and molecularly. Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP), Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animals underwent bilateral ovariectomy. RAMEL was administered orally once a day in the prophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy. Results: Fourteen weeks after ovariectomy, there was a significant reduction in femoral bone mineral density (BMD) (g/cm2) in the OP group compared to the control group. Compared to the OP group, RAMEL treatment significantly increased the BMD level (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2 (RUNX2) mRNA levels were significantly lower in the OP group than in the control group (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in the RAMEL treatment groups than in the OP group (p<0.05). Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, a peripheral melatonin agonist, can be used to prevent osteoporosis.en_US
dc.language.isoengen_US
dc.relation.isversionof10.30565/medalanya.939161en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRamelteon, melatonin, osteoporosis, boneen_US
dc.subjectRamelteonen_US
dc.subjectMelatoninen_US
dc.subjectOsteoporosisen_US
dc.subjectBoneen_US
dc.titleRamelteon used to treat insomnia can reduce the occurrence of osteoporosisen_US
dc.typearticleen_US
dc.contributor.departmentALKÜen_US
dc.identifier.volume5en_US
dc.identifier.issue2en_US
dc.identifier.startpage164en_US
dc.identifier.endpage170en_US
dc.relation.journalActa Medica Alanyaen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Başka Kurum Yazarıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster